Home » AstraZeneca Licenses Three X-Chem Drug Discovery Programs
AstraZeneca Licenses Three X-Chem Drug Discovery Programs
AstraZeneca is licensing three programs of X-Chem aimed at parsing out protein-protein interactions for oncology and respiratory/inflammation purposes. X-Chem is getting an up-front payment, as well as research funding, out of the deal.
Genetic Engineering & Biotechnology News
Genetic Engineering & Biotechnology News
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May